CERE - Cerevel shares surge on topline results from CVL-231 early-stage schizophrenia study

Cerevel Therapeutics (CERE) shares jump more than 30% during premarket trading after the company posted positive results from its early-stage trial of CVL-231, a novel muscarinic M4-selective Positive Allosteric Modulator ((PAM)), in adult patients with schizophrenia.Both the 30 mg once-daily and the 20 mg twice-daily doses of the treatment showed clinically meaningful antipsychotic activity with an overall well-tolerated profile compared with placebo.The 30 mg dose resulted in mean reduction from baseline of 19.5 points in the Positive and Negative Syndrome Scale ((PANSS)) total score and a mean reduction of 12.7 points in PANSS vs the placebo group (p=0.023).The 20 mg dose resulted in mean reduction from baseline of 17.9 points in PANSS total score and a mean reduction of 11.1 points in PANSS total score compared with the placebo group (p=0.047).CVL-231 was generally well-tolerated in the trial with the incidence of treatment emergent adverse events for both dose cohorts being similar to placebo, including

For further details see:

Cerevel shares surge on topline results from CVL-231 early-stage schizophrenia study